Healthcare utilization and indirect cost of treatment associated with severe allergic asthma in a real-world setting

Table 1

Variable, mean (SD); n	Pre-treatment° (N=916)	12 months (N=734)	24 months (N=643)
Asthma-related hospitalizations	0.7 (1.32); 882	0.1 (0.43); 702	0.1 (0.41); 628
Duration of hospitalization stay due to asthma, days	5.3 (11.05); 852	0.7 (3.84); 703	0.5 (3.39); 628
Asthma-related emergency room visits	1.8 (2.87); 867	0.2 (0.64); 700	0.1 (0.32); 627
Unscheduled asthma-related doctor visits	3.8 (4.79); 823	0.7 (1.43); 684	0.4 (0.99); 619
Asthma-related medical healthcare uses*	6.2 (6.97); 811	1.0 (1.96); 684	0.5 (1.28); 618
Absence from work due to asthma^#, days	26.4 (49.61); 347	3.5 (17.28); 295	1.0 (4.66); 296
Absence from school due to asthma^#, days	20.7 (27.49); 57	1.6 (4.28); 59	1.9 (5.46); 58

Table 1 shows annualized data (12 month combined 16 weeks, 8 and 12 month data; 24 month combined 18 and 24 month data).
n – number of patients with data recorded. ° Within 12 months prior to start of omalizumab treatment. *Total number of asthma-related healthcare uses was calculated if data for asthma-related hospitalizations, emergency room visits and unscheduled doctor visits were available. ^#Excluded those patients for whom this category was not applicable. Conclusion: Results from the eXpeRience registry showed that omalizumab reduced healthcare utilization and the number of days missed from school or work by asthma patients in a real-world setting. Thus, omalizumab treatment was associated with a positive and substantial impact on the direct and indirect costs linked with uncontrolled SAA.

ISSN: 2045-7022